Drugs / IDE892
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07277413 | Mar 2026 → Apr 2028 expected | biliary tract cancer, esophageal adenocarcinoma, esophageal squamous cell carcinoma, gastric adenocarcinoma +7 | IDEAYA Biosciences | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2026-03-18 | IDEAYA Biosciences | Results IDEAYA Biosciences Announces Upcoming Presentations at AACR 2026 Highlighting Multiple Clinical Stage Pipeline Programs ideayabio.com ↗
IDE892 is a highly potent and selective PRMT5 inhibitor, with MTA-positive and SAM-negative cooperativity, optimized for development in MTAP-del cancers in combination with the allosteric MAT2A inhibitor IDE397 |
| 2025-09-03 | IDEAYA Biosciences | Regulatory IDEAYA Biosciences Announces IND Submission for IDE892, a Potential Best-In-Class PRMT5 Inhibitor for MTAP-Deletion Solid Tumors ideayabio.com ↗
announced the submission of an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) for IDE892, a potential best-in-class MTA-cooperative inhibitor of PRMT5. |
All press releases naming this drug 6 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IDE892 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07277413 ↗ |
| Action | Inhibit | “IDE892 is an inhibitor of the Protein arginine methyltransferase 5 (PRMT5)” NCT07277413 ↗ |
| Target | PRMT5 | “IDE892 is an inhibitor of the Protein arginine methyltransferase 5 (PRMT5)” NCT07277413 ↗ |